Our patents :
1.EP 3 167 048 B1 2.WO 2017/103025
We offer the following services for :
- Discovery and early screening: Screening on different cancers and lead selection.
- Preclinical efficacy and lead validation : In-house predictive PDX models enable lead validation, biomarker discovery for your future clinical trials and patient stratification.
- Translational biomarker Discovery
We can test all types of drugs (small molecules, targeted therapies). Our technology allows for:
- Creating novel cancer models
- Mimicking clinical trials
- Identifying biomarkers of patient response and resistance
- Quantitative analysis of molecule efficacy
- Assessing patient response heterogeneity and predicting patient tumor sensitivity/resistance to drug
- Assessing tumor aspect, metastasis (localized/metastatic tumor pattern)
Available PDX models and subtypes
Cancers successfully replicated in our model:
|TN (ER–, PR–, HER2–)||Cisplatin, Gemcitabine, Carboplatin|
|Glioma||OA, IDHmut, 1p19qcodel|
|OA, IDHmut, 1p19qwt|
|Stage M, MYCN amplified||Vincristine|
|Stage M, MYCN not amplified||Vincristine|
|Germ Cell Tumors||Type I, yolk sac||Cisplatin|
|Type II, mixed testicular||Cisplatin|
Custom- made models :
Oncofactory elaborates custom-made models to answer specific needs of clients. Please contact us to discuss your project.